Online inquiry

IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13270MR)

This product GTTS-WQ13270MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13270MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1452MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ4590MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ13878MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ11357MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ14274MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ7331MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ2656MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ15591MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW